Skip to main content

Table 2 Main reasons anticoagulant not used in males with CHA2DS2-VASc ≥2, and females with CHA2DS2-VASc ≥3

From: Changes in anticoagulant prescription in Dutch patients with recent-onset atrial fibrillation: observations from the GARFIELD-AF registry

 Netherlands (N = 66)
n (%)
World (N = 11,630)
n (%)
Alcohol abuse0 (0.0)48 (0.4)
Already taking AP for other medical condition3 (4.5)628 (5.4)
Patient refusal1 (1.5)911 (7.8)
Previous bleeding event2 (3.0)211 (1.8)
Taking medication contraindicated or cautioned for use with OAC1 (1.5)78 (0.7)
Other12 (18.2)1682 (14.5)
Unknown19 (28.8)4588 (39.4)
Physician’s choice28 (42.4)3484 (30.0)
 Bleeding risk5 (7.6)836 (7.2)
 Concern over patient compliance0 (0.0)412 (3.5)
 Guideline recommendation0 (0.0)237 (2.0)
 Fall risk0 (0.0)401 (3.4)
 Low risk of stroke8 (12.1)677 (5.8)
 Other15 (22.7)921 (7.9)
  1. AP Antiplatelet drug, OAC Oral anticoagulation